Skip to main content
SpringerLink
Log in

Making a Case to Continue Considering Treatment with Selective Serotonin Reuptake Inhibitors for Children with Autism Spectrum Disorders

  • INVITED COMMENTARY
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010;8:CD004677.

    PubMed  Google Scholar 

  2. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Arch Gen Psychiatry. 2009;66(6):583–90.

    Article  PubMed  CAS  Google Scholar 

  3. Barthelemy C, Bruneau N, Jouve J, et al. Urinary dopamine metabolites as indicators of the responsiveness of fenfluramine treatment in children with autistic behavior. J Autism Dev Disord. 1989;19(2):241–54.

    Article  PubMed  CAS  Google Scholar 

  4. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology. 2005;30:582–9.

    Article  PubMed  CAS  Google Scholar 

  5. Leventhal B, Cook E, Morford M, et al. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatry. 1993;5(3):307–15.

    CAS  Google Scholar 

  6. Sugie Y, Sugie H, Kukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J Autism Dev Disord. 2005;35(3):377–85.

    Article  PubMed  Google Scholar 

  7. Buchsbaum M, Hollander E, Haznedar M, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol. 2001;4:119–25.

    Article  PubMed  CAS  Google Scholar 

  8. McDougle C, Naylor S, Cohen D, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001–8.

    PubMed  CAS  Google Scholar 

  9. Volkmar F, Cook Jr EH, Pomeroy J, et al. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry. 1999;38(12 Suppl):32S–54S.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflict of interest relevant to this article was reported.

Author information

Authors and Affiliations

  1. Division of Child and Adolescent Psychiatry, Departments of Child Psychiatry and Pediatrics, Stanford University School of Medicine, 401 Quarry Road, MC-5719, Stanford, CA, 94305, USA

    Wendy Froehlich

Authors
  1. Wendy Froehlich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy Froehlich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Froehlich, W. Making a Case to Continue Considering Treatment with Selective Serotonin Reuptake Inhibitors for Children with Autism Spectrum Disorders. Curr Psychiatry Rep 13, 170–173 (2011). https://doi.org/10.1007/s11920-011-0196-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-011-0196-0

Keywords

Search

Navigation